Peter Elliott

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP): Updated Analyst Ratings

ZIOPHARM Oncology, Inc. (ZIOP) down -8.14 per cent in the past week, is under coverage of 5 analysts who collectively recommend a hold rating on stock. 1 of the analysts have a buy or better rating; the 1 sells versus 0 underperforms. The 2 equity analysts who rate the stock have an average target price at $14, with individual targets ranging between $7 and $21. The shares closed last trade at $7.11, implying that analysts see shares rising about 96.91 per cent in 12 months’ time.

Insider Activity: Insiders look pessimistic about the prospects of the company that they seem to offload shares while they are -14.44 down so far this year. A COO, CLO, and Secretary at ZIOPHARM Oncology, Inc. (ZIOP) sold shares in the company in a transaction completed on Thursday November 19, 2015. Belbel Caesar J offloaded 153,333 shares in the company at an average price of $12.84 and ended up generating $1,968,800 in proceeds. Belbel Caesar J retains 59,201 shares in the company after this transaction. A Executive Vice President R&D in the company, Lebel Francois, on Tuesday June 09, 2015 collected $506,000 from the sale of 50,000 shares at $12.84 each. Insiders are expected to know better about the health and prospects of their company, which is why insiders’ move deserves attention.

Earnings to Watch: Investors considering ZIOP stock at the going market price of $7.11/share should know the stock will next release quarterly results for the June 2016 quarter. For the reporting quarter, analysts expect the company to deliver -$0.11 in earnings per share (EPS). That would represent a 0% year-over-year decrease. Revenue for the same period is expected to arrive at $1.76M.

Earnings Roundup: In the last fiscal quarter alone, ZIOPHARM Oncology, Inc. generated around $1.97M in revenue. That compares with the consensus estimate $1.49M. For the prior quarter revenue for the company hit $1.92M, with earnings at -$0.07/share.

Analyst Coverage: Raymond James has been a brokerage house following shares of ZIOPHARM Oncology, Inc. (ZIOP), so its rating change is noteworthy. The stock was initiated at Mkt Perform, wrote analysts at Raymond James, in a note issued to clients on Thursday June 02, 2016. There was another key note issued by Mizuho on Tuesday March 10, 2015. The firm lowered its rating on ZIOP from Buy to Neutral.

Price Momentum: Despite the -1.66% decrease in value, the stock’s new closing price represents a -52.38% fall in value from company’s one year high of $14.93. The stock is currently holding above its 50 day moving average of $-7.41 and below its 200 day moving average of $7.45. Over the last three months and over the last six months, the shares of ZIOPHARM Oncology, Inc. (ZIOP), have changed -19.38% and 7.77%, respectively.

 

American Capital, Ltd. (NASDAQ:ACAS) Earns Consensus Hold Rating

American Capital, Ltd. (ACAS) down -0.56 per cent in the past week, is under coverage of 7 analysts who collectively recommend a hold rating on stock. 4 of the analysts have a buy or better rating; the 0 sells versus 1 underperforms. The 5 equity analysts who rate the stock have an average target price at $17, with individual targets ranging between $14.5 and $18. The shares closed last trade at $15.97, implying that analysts see shares rising about 6.45 per cent in 12 months’ time.

Insider Activity: Insiders look pessimistic about the prospects of the company that they seem to offload shares while they are 15.81 up so far this year. A EVP and Senior Managing Dir. at American Capital, Ltd. (ACAS) sold shares in the company in a transaction completed on Wednesday May 11, 2016. Mchale Thomas offloaded 9,631 shares in the company at an average price of $15.92 and ended up generating $153,330 in proceeds. Mchale Thomas retains 179,028 shares in the company after this transaction. A President, Private Finance in the company, Graff Brian, on Wednesday May 11, 2016 collected $21,610 from the sale of 1,350 shares at $15.92 each. Insiders are expected to know better about the health and prospects of their company, which is why insiders’ move deserves attention.

Earnings to Watch: Investors considering ACAS stock at the going market price of $15.97/share should know the stock will next release quarterly results for the June 2016 quarter. For the reporting quarter, analysts expect the company to deliver $0.28 in earnings per share (EPS). That would represent a -17.65% year-over-year decrease. Revenue for the same period is expected to arrive at $129.64M.

Earnings Roundup: In the last fiscal quarter alone, American Capital, Ltd. generated around $162M in revenue. That compares with the consensus estimate $132.1M. For the prior quarter revenue for the company hit $173M, with earnings at $0.37/share.

Analyst Coverage: Cantor Fitzgerald has been a brokerage house following shares of American Capital, Ltd. (ACAS), so its rating change is noteworthy. The stock was upgraded to Buy from Hold, wrote analysts at Cantor Fitzgerald, in a note issued to clients on Friday November 06, 2015. There was another key note issued by Cantor Fitzgerald on Wednesday July 01, 2015. The firm launched coverage on ACAS at Hold.

Price Momentum: Despite the -0.13% decrease in value, the stock’s new closing price represents a -1.36% fall in value from company’s one year high of $16.19. The stock is currently holding above its 50 day moving average of $1.67 and above its 200 day moving average of $15.84. Over the last three months and over the last six months, the shares of American Capital, Ltd. (ACAS), have changed 12.74% and 14.66%, respectively.

The Insider Activity Don’t Lie: Ashford Hospitality Prime, Inc. (NYSE:AHP)

Ashford Hospitality Prime, Inc. (AHP) up 35.08 per cent in the past week, is under coverage of 7 analysts who collectively recommend a hold rating on stock. 1 of the analysts have a buy or better rating; the 0 sells versus 1 underperforms. The 7 equity analysts who rate the stock have an average target price at $12.5, with individual targets ranging between $10.5 and $16. The shares closed last trade at $14.71, implying that analysts see shares falling about -15.02 per cent in 12 months’ time.

Insider Activity: Insiders look pessimistic about the prospects of the company that they seem to offload shares while they are 1.45 up so far this year. A President at Ashford Hospitality Prime, Inc. (AHP) sold shares in the company in a transaction completed on Tuesday September 01, 2015. Kessler Douglas A offloaded 2,441 shares in the company at an average price of $15 and ended up generating $36,620 in proceeds. Kessler Douglas A retains 101,294 shares in the company after this transaction. A President in the company, Kessler Douglas A, on Monday July 27, 2015 collected $582,470 from the sale of 38,600 shares at $15 each. Insiders are expected to know better about the health and prospects of their company, which is why insiders’ move deserves attention.

Earnings to Watch: Investors considering AHP stock at the going market price of $14.71/share should know the stock will next release quarterly results for the June 2016 quarter. For the reporting quarter, analysts expect the company to deliver $0.66 in earnings per share (EPS). That would represent a 10% year-over-year increase. Revenue for the same period is expected to arrive at $114.56M.

Earnings Roundup: In the last fiscal quarter alone, Ashford Hospitality Prime, Inc. generated around $99.8M in revenue and net income of -$0.04/share. That compares with the consensus estimate $97.52M and $0.03/share, respectively. For the prior quarter revenue for the company hit $88.16M, with earnings at $0.22/share.

Analyst Coverage: Robert W. Baird has been a brokerage house following shares of Ashford Hospitality Prime, Inc. (AHP), so its rating change is noteworthy. The stock was upgraded to Neutral from Underperform, wrote analysts at Robert W. Baird, in a note issued to clients on Tuesday March 29, 2016. There was another key note issued by Sun Trust Rbsn Humphrey on Friday February 05, 2016. The firm lowered its rating on AHP from Buy to Neutral.

Price Momentum: Despite the 29.95% increase in value, the stock’s new closing price represents a -8.67% fall in value from company’s one year high of $17.34. The stock is currently holding below its 50 day moving average of $30.3 and above its 200 day moving average of $11.41. Over the last three months and over the last six months, the shares of Ashford Hospitality Prime, Inc. (AHP), have changed 17.15% and 11.63%, respectively.

 

Galena Biopharma, Inc. (NASDAQ:GALE) Earns Consensus Buy Rating

Galena Biopharma, Inc. (GALE) down -5.09 per cent in the past week, is under coverage of 5 analysts who collectively recommend a buy rating on stock. 5 of the analysts have a buy or better rating; the 0 sells versus 0 underperforms. The 5 equity analysts who rate the stock have an average target price at $3.9, with individual targets ranging between $2 and $5. The shares closed last trade at $2.05, implying that analysts see shares rising about 90.24 per cent in 12 months’ time.

Insider Activity: Insiders look pessimistic about the prospects of the company that they seem to offload shares while they are 39.46 up so far this year. A Former CFO at Galena Biopharma, Inc. (GALE) sold shares in the company in a transaction completed on Wednesday June 01, 2016. Dunlap Ryan offloaded 126,875 shares in the company at an average price of $2.18 and ended up generating $276,590 in proceeds. Dunlap Ryan retains 18,702 shares in the company after this transaction. A Director in the company, Chin Richard, on Wednesday February 12, 2014 collected $811,880 from the sale of 187,500 shares at $2.18 each. Insiders are expected to know better about the health and prospects of their company, which is why insiders’ move deserves attention.

Earnings Roundup: In the last fiscal quarter alone, Galena Biopharma, Inc. generated around $0 in revenue and net income of -$0.09/share. That compares with the consensus estimate $0 and -$0.06/share, respectively. For the prior quarter revenue for the company hit $1.44M, with earnings at -$0.12/share.

Analyst Coverage: Oppenheimer has been a brokerage house following shares of Galena Biopharma, Inc. (GALE), so its rating change is noteworthy. The stock was upgraded to Outperform from Perform, wrote analysts at Oppenheimer, in a note issued to clients on Thursday November 12, 2015. There was another key note issued by Raymond James on Wednesday September 09, 2015. The firm launched coverage on GALE at Outperform.

Price Momentum: Despite the 1.49% increase in value, the stock’s new closing price represents a -14.23% fall in value from company’s one year high of $2.29. The stock is currently holding below its 50 day moving average of $34.94 and above its 200 day moving average of $1.54. Over the last three months and over the last six months, the shares of Galena Biopharma, Inc. (GALE), have changed 50.09% and 1.24%, respectively.

 

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Stock Rises, Analysts: Hold Rating

Arena Pharmaceuticals, Inc. (ARNA) up 20.11 per cent in the past week, is under coverage of 7 analysts who collectively recommend a hold rating on stock. 2 of the analysts have a buy or better rating; the 0 sells versus 0 underperforms. The 3 equity analysts who rate the stock have an average target price at $3, with individual targets ranging between $1.5 and $4. The shares closed last trade at $2.15, implying that analysts see shares rising about 39.53 per cent in 12 months’ time.

Insider Activity: Insiders look pessimistic about the prospects of the company that they seem to offload shares while they are 13.16 up so far this year. A Director at Arena Pharmaceuticals, Inc. (ARNA) sold shares in the company in a transaction completed on Monday March 30, 2015. Woods Randall E offloaded 76,268 shares in the company at an average price of $4.49 and ended up generating $342,440 in proceeds. Woods Randall E retains 45,112 shares in the company after this transaction. A EVP, General Counsel & Sec in the company, Spector Steven W, on Tuesday March 17, 2015 collected $350,000 from the sale of 70,000 shares at $4.49 each. Insiders are expected to know better about the health and prospects of their company, which is why insiders’ move deserves attention.

Earnings to Watch: Investors considering ARNA stock at the going market price of $2.15/share should know the stock will next release quarterly results for the June 2016 quarter. For the reporting quarter, analysts expect the company to deliver -$0.1 in earnings per share (EPS). That would represent a -9.09% year-over-year decrease. Revenue for the same period is expected to arrive at $9.54M.

Earnings Roundup: In the last fiscal quarter alone, Arena Pharmaceuticals, Inc. generated around $9.85M in revenue and net income of -$0.09/share. That compares with the consensus estimate $9.02M and -$0.1/share, respectively. For the prior quarter revenue for the company hit $7.75M, with earnings at -$0.11/share.

Analyst Coverage: RBC Capital Mkts has been a brokerage house following shares of Arena Pharmaceuticals, Inc. (ARNA), so its rating change is noteworthy. The stock was initiated at Sector Perform, wrote analysts at RBC Capital Mkts, in a note issued to clients on Friday January 23, 2015. There was another key note issued by WallachBeth on Friday November 15, 2013. The firm launched coverage on ARNA at Buy.

Price Momentum: Despite the 9.69% increase in value, the stock’s new closing price represents a -58.01% fall in value from company’s one year high of $5.12. The stock is currently holding below its 50 day moving average of $21.94 and above its 200 day moving average of $1.7. Over the last three months and over the last six months, the shares of Arena Pharmaceuticals, Inc. (ARNA), have changed 11.85% and 1.74%, respectively.

 

VEREIT, Inc. (NYSE:VER) Insider Activities Are in the Air

VEREIT, Inc. (VER) up 1.88 per cent in the past week, is under coverage of 9 analysts who collectively recommend a hold rating on stock. 2 of the analysts have a buy or better rating; the 0 sells versus 0 underperforms. The 6 equity analysts who rate the stock have an average target price at $10.46, with individual targets ranging between $9.75 and $11. The shares closed last trade at $9.77, implying that analysts see shares rising about 7.06 per cent in 12 months’ time.

Insider Activity: Insiders look optimistic about the prospects of the company that they seem to accumulate shares while they are 23.36 up so far this year. A See Remarks at VEREIT, Inc. (VER) purchased shares in the company in a transaction completed on Monday December 14, 2015. Mcdowell Paul H accumulated 6,000 shares in the company at an average price of $7.93 and ended up spending $47,580 in the investment. Mcdowell Paul H now have 70,741 shares in the company after this transaction. A Director in the company, Pinover Eugene A, on Thursday November 12, 2015 spent $99,880 from the purchase of 12,300 shares at $7.93 each. Insiders are expected to know better about the health and prospects of their company, which is why insiders’ move deserves attention.

Earnings to Watch: Investors considering VER stock at the going market price of $9.77/share should know the stock will next release quarterly results for the June 2016 quarter. For the reporting quarter, analysts expect the company to deliver $0.19 in earnings per share (EPS). That would represent a -13.64% year-over-year decrease. Revenue for the same period is expected to arrive at $323.59M.

Earnings Roundup: In the last fiscal quarter alone, VEREIT, Inc. generated around $313.97M in revenue. That compares with the consensus estimate $329.04M. For the prior quarter revenue for the company hit $350.06M, with earnings at $0.2/share.

Analyst Coverage: CapitalOne has been a brokerage house following shares of VEREIT, Inc. (VER), so its rating change is noteworthy. The stock was downgraded to Equal Weight from Overweight, wrote analysts at CapitalOne, in a note issued to clients on Monday December 21, 2015. There was another key note issued by JP Morgan on Friday November 06, 2015. The firm lifted its rating on VER from Underweight to Neutral.

Price Momentum: Despite the 0.21% increase in value, the stock’s new closing price represents a -1.71% fall in value from company’s one year high of $9.94. The stock is currently holding above its 50 day moving average of $5.83 and above its 200 day moving average of $9.39. Over the last three months and over the last six months, the shares of VEREIT, Inc. (VER), have changed 17.06% and 8.45%, respectively.

 

The Insider Activity Don’t Lie: New York Community Bancorp Inc. (NYSE:NYCB)

New York Community Bancorp Inc. (NYCB) down -1.52 per cent in the past week, is under coverage of 15 analysts who collectively recommend a hold rating on stock. 6 of the analysts have a buy or better rating; the 0 sells versus 2 underperforms. The 14 equity analysts who rate the stock have an average target price at $16.57, with individual targets ranging between $14.5 and $20. The shares closed last trade at $15.5, implying that analysts see shares rising about 6.9 per cent in 12 months’ time.

Insider Activity: Insiders look optimistic about the prospects of the company that they seem to accumulate shares while they are -2.84 down so far this year. A Director at New York Community Bancorp Inc. (NYCB) purchased shares in the company in a transaction completed on Wednesday May 04, 2016. Ciampa Dominick accumulated 10,000 shares in the company at an average price of $14.48 and ended up spending $144,800 in the investment. Ciampa Dominick now have 740,642 shares in the company after this transaction. A Director in the company, Ciampa Dominick, on Wednesday March 23, 2016 spent $158,100 from the purchase of 10,000 shares at $14.48 each. Insiders are expected to know better about the health and prospects of their company, which is why insiders’ move deserves attention.

Earnings to Watch: Investors considering NYCB stock at the going market price of $15.5/share should know the stock will next release quarterly results for the June 2016 quarter. For the reporting quarter, analysts expect the company to deliver $0.28 in earnings per share (EPS). That would represent a 0% year-over-year decrease. Revenue for the same period is expected to arrive at $329.13M.

Earnings Roundup: In the last fiscal quarter alone, New York Community Bancorp Inc. generated around $327.87M in revenue and net income of $0.27/share. That compares with the consensus estimate $323.53M and $0.28/share, respectively. For the prior quarter revenue for the company hit $-450000000, with earnings at $0.31/share.

Analyst Coverage: FBR Capital has been a brokerage house following shares of New York Community Bancorp Inc. (NYCB), so its rating change is noteworthy. The stock was upgraded to Mkt Perform from Underperform, wrote analysts at FBR Capital, in a note issued to clients on Tuesday January 19, 2016. There was another key note issued by Sterne Agee CRT on Tuesday January 05, 2016. The firm lifted its rating on NYCB from Neutral to Buy.

Price Momentum: Despite the -1.02% decrease in value, the stock’s new closing price represents a -16.04% fall in value from company’s one year high of $19.18. The stock is currently holding above its 50 day moving average of $2.03 and above its 200 day moving average of $15.19. Over the last three months and over the last six months, the shares of New York Community Bancorp Inc. (NYCB), have changed -2.34% and 15.58%, respectively.

Rice Energy Inc. (NYSE:RICE) Insiders Look Pessimistic About Prospects

Rice Energy Inc. (RICE) up 5.83 per cent in the past week, is under coverage of 26 analysts who collectively recommend a buy rating on stock. 20 of the analysts have a buy or better rating; the 0 sells versus 0 underperforms. The 22 equity analysts who rate the stock have an average target price at $22.39, with individual targets ranging between $16 and $30. The shares closed last trade at $21.43, implying that analysts see shares rising about 4.48 per cent in 12 months’ time.

Insider Activity: Insiders look pessimistic about the prospects of the company that they seem to offload shares while they are 96.61 up so far this year. A Director, 10% Owner at Rice Energy Inc. (RICE) sold shares in the company in a transaction completed on Friday April 15, 2016. Ngp Rice Holdings Llc offloaded 9,858,891 shares in the company at an average price of $15.6 and ended up generating $154,000,000 in proceeds. Ngp Rice Holdings Llc retains 4,478,834 shares in the company after this transaction. A 10% Owner in the company, Rice Energy Irrevocable Trust, on Monday December 21, 2015 collected $38,750,000 from the sale of 5,000,000 shares at $15.6 each. Insiders are expected to know better about the health and prospects of their company, which is why insiders’ move deserves attention.

Earnings to Watch: Investors considering RICE stock at the going market price of $21.43/share should know the stock will next release quarterly results for the June 2016 quarter. For the reporting quarter, analysts expect the company to deliver -$0.07 in earnings per share (EPS). That would represent a -333.33% year-over-year decrease. Revenue for the same period is expected to arrive at $178.44M.

Earnings Roundup: In the last fiscal quarter alone, Rice Energy Inc. generated around $139.94M in revenue and net income of $0.02/share. That compares with the consensus estimate $162.91M and -$0.09/share, respectively. For the prior quarter revenue for the company hit $136.09M, with earnings at $0.16/share.

Analyst Coverage: Drexel Hamilton has been a brokerage house following shares of Rice Energy Inc. (RICE), so its rating change is noteworthy. The stock was initiated at Buy, wrote analysts at Drexel Hamilton, in a note issued to clients on Thursday February 18, 2016. There was another key note issued by Goldman on Wednesday November 11, 2015. The firm lowered its rating on RICE from Buy to Neutral.

Price Momentum: Despite the 3.98% increase in value, the stock’s new closing price represents a -9.46% fall in value from company’s one year high of $23.67. The stock is currently holding below its 50 day moving average of $25.03 and above its 200 day moving average of $18.37. Over the last three months and over the last six months, the shares of Rice Energy Inc. (RICE), have changed 49.7% and 12.95%, respectively.